Prolonging survival in patients with AML ineligible for intensive chemotherapy 

Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses strategies to prolong survival in patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy. He notes the success of combining azacitidine and venetoclax and suggests focusing on adding non-myelosuppressive agents to enhance this combination's efficacy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.